JP7733020B2 - 免疫調節性化合物 - Google Patents

免疫調節性化合物

Info

Publication number
JP7733020B2
JP7733020B2 JP2022574459A JP2022574459A JP7733020B2 JP 7733020 B2 JP7733020 B2 JP 7733020B2 JP 2022574459 A JP2022574459 A JP 2022574459A JP 2022574459 A JP2022574459 A JP 2022574459A JP 7733020 B2 JP7733020 B2 JP 7733020B2
Authority
JP
Japan
Prior art keywords
peptide
seq
amino acid
acid sequence
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022574459A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023529839A (ja
JP2023529839A5 (https=
Inventor
ガブリエル エム． グティエレス，
ジェイムズ パヌッチ，
ヴィナヤカ コトライア，
ティモシー ダブリュー． ファレス，
セシル ディー． ブラウン，
Original Assignee
レイドス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by レイドス， インコーポレイテッド filed Critical レイドス， インコーポレイテッド
Publication of JP2023529839A publication Critical patent/JP2023529839A/ja
Publication of JP2023529839A5 publication Critical patent/JP2023529839A5/ja
Application granted granted Critical
Publication of JP7733020B2 publication Critical patent/JP7733020B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2022574459A 2020-06-04 2021-06-03 免疫調節性化合物 Active JP7733020B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063034554P 2020-06-04 2020-06-04
US63/034,554 2020-06-04
PCT/US2021/035580 WO2021247789A1 (en) 2020-06-04 2021-06-03 Immunomodulatory compounds

Publications (3)

Publication Number Publication Date
JP2023529839A JP2023529839A (ja) 2023-07-12
JP2023529839A5 JP2023529839A5 (https=) 2024-06-10
JP7733020B2 true JP7733020B2 (ja) 2025-09-02

Family

ID=76695836

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022574459A Active JP7733020B2 (ja) 2020-06-04 2021-06-03 免疫調節性化合物

Country Status (6)

Country Link
US (1) US11338040B2 (https=)
EP (1) EP4161952A1 (https=)
JP (1) JP7733020B2 (https=)
AU (1) AU2021283353A1 (https=)
CA (1) CA3185657A1 (https=)
WO (1) WO2021247789A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020237050A1 (en) 2019-05-22 2020-11-26 Leidos, Inc. Lag3 binding peptides
AU2021316230A1 (en) 2020-07-31 2023-03-16 Leidos, Inc. LAG3 binding peptides
EP4225444A1 (en) * 2020-10-12 2023-08-16 Leidos, Inc. Immunomodulatory peptides
WO2025193573A1 (en) * 2024-03-11 2025-09-18 Bristol-Myers Squibb Company Macrocyclic peptides useful as immunomodulators

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105504018A (zh) 2016-01-13 2016-04-20 郑州大学 Lag-3亲和肽n13、制备方法及其应用
JP2017535527A (ja) 2014-10-01 2017-11-30 プロタゴニスト セラピューティクス， インコーポレイテッド 新規のα４β７ペプチド単量体及び二量体拮抗薬
JP2018526989A (ja) 2015-08-07 2018-09-20 ピエリス ファーマシューティカルズ ゲーエムベーハー Ｌａｇ−３およびｐｄ−１に特異的な新規融合ポリペプチド
WO2018218137A1 (en) 2017-05-25 2018-11-29 Leidos, Inc. Pd-1 and ctla-4 dual inhibitor peptides
WO2019158942A1 (en) 2018-02-16 2019-08-22 Crescendo Biologics Limited Therapeutic molecules that bind to lag3 and pd1

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001523958A (ja) 1997-03-21 2001-11-27 ブライハム アンド ウィミンズ ホスピタル，インコーポレイテッド 免疫療法のｃｔｌａ−４結合ペプチド
JP2002513811A (ja) 1998-05-06 2002-05-14 ファルマシア・アンド・アップジョン・カンパニー 非−ヒト脊椎動物への、非−ヒト脊椎動物のペプチドホルモンまたはサイトカインをコードする裸のｄｎａまたは裸のｒｎａの導入
CA2541006C (en) 2003-10-03 2015-02-17 Brigham And Women's Hospital Tim-3 polypeptides
BR112012007875A2 (pt) 2009-07-31 2016-11-22 Medarex Inc anticorpos totalmente humanos para btla
US20130202623A1 (en) 2010-02-16 2013-08-08 Nicolas Chomont Pd-1 modulation and uses thereof for modulating hiv replication
MX2012009632A (es) 2010-02-18 2012-09-28 Athenix Corp Genes delta-endotoxinicos axmi221z, axmi222z, axmi223z, axmi224z, axmi225z y metodos para su uso.
MX374075B (es) 2010-03-26 2025-03-05 Dartmouth College Proteina mediadora de celula t regulatoria vista, agentes de enlace de vista y uso de los mismos.
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
US20130267515A1 (en) 2010-10-26 2013-10-10 Alberta Health Services Combination comprising an atp analog and an adenosine receptor antagonist or a nucleobase/nucleoside analog for the treatment of cancer
CN102085735B (zh) 2010-11-09 2013-03-27 浙江大东南包装股份有限公司 一种多功能bopp烟用包装膜及其制造方法
WO2012116714A1 (en) 2011-03-02 2012-09-07 Curevac Gmbh Vaccination in elderly patients
WO2012168944A1 (en) 2011-06-08 2012-12-13 Aurigene Discovery Technologies Limited Therapeutic compounds for immunomodulation
WO2013132317A1 (en) 2012-03-07 2013-09-12 Aurigene Discovery Technologies Limited Peptidomimetic compounds as immunomodulators
CA2868408A1 (en) 2012-03-29 2013-10-03 Aurigene Discovery Technologies Limited Immunomodulating cyclic compounds from the bc loop of human pd1
US9381244B2 (en) 2012-09-07 2016-07-05 King's College London VISTA modulators for diagnosis and treatment of cancer
PL2904011T3 (pl) 2012-10-02 2018-01-31 Bristol Myers Squibb Co Połączenie przeciwciał anty-kir i przeciwciał anty-pd-1 w leczeniu raka
US9974845B2 (en) 2013-02-22 2018-05-22 Curevac Ag Combination of vaccination and inhibition of the PD-1 pathway
US9320706B2 (en) 2013-03-13 2016-04-26 Transdermal Biotechnology, Inc. Immune modulation using peptides and other compositions
US9295647B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Systems and methods for delivery of peptides
US20160145355A1 (en) 2013-06-24 2016-05-26 Biomed Valley Discoveries, Inc. Bispecific antibodies
CN104072615B (zh) 2014-01-26 2016-08-24 中国人民解放军军事医学科学院基础医学研究所 一种能阻断Tim-3信号通路的人Tim-3融合蛋白
HUE045065T2 (hu) 2014-01-31 2019-12-30 Novartis Ag TIM-3 antitest molekulák és felhasználásaik
US10899840B2 (en) 2014-02-04 2021-01-26 Pfizer Inc. Combination of a PD-1 antagonist and a 4-1BB agonist for treating cancer
SG11201606428UA (en) 2014-02-04 2016-09-29 Incyte Corp Combination of a pd-1 antagonist and an ido1 inhibitor for treating cancer
ES2833425T3 (es) 2014-07-16 2021-06-15 Roussy Inst Gustave Combinación de virus oncolítico con moduladores de punto de control inmunitario
JO3663B1 (ar) 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
US10695426B2 (en) 2014-08-25 2020-06-30 Pfizer Inc. Combination of a PD-1 antagonist and an ALK inhibitor for treating cancer
US10016480B2 (en) 2014-10-14 2018-07-10 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Peptide-based methods for treating pancreatic cancer
BR112017007765B1 (pt) 2014-10-14 2023-10-03 Halozyme, Inc Composições de adenosina deaminase-2 (ada2), variantes do mesmo e métodos de usar o mesmo
CA2994241A1 (en) 2015-07-31 2017-02-09 University Of Florida Research Foundation, Inc. Hematopoietic stem cells in combinatorial therapy with immune checkpoint inhibitors against cancer
TWI756187B (zh) 2015-10-09 2022-03-01 美商再生元醫藥公司 抗ｌａｇ３抗體及其用途
US9957325B2 (en) 2015-10-13 2018-05-01 Formurex, Inc. Synthetic antibody mimic peptides
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
US10098950B2 (en) 2016-09-15 2018-10-16 Leidos, Inc. PD-1 Peptide Inhibitors
US10799555B2 (en) 2016-09-15 2020-10-13 Leidos, Inc. PD-1 peptide inhibitors
CN107383174B (zh) 2017-08-21 2019-01-18 生工生物工程（上海）股份有限公司 一种能与pd-1特异性结合的肿瘤抑制肽及其用途

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017535527A (ja) 2014-10-01 2017-11-30 プロタゴニスト セラピューティクス， インコーポレイテッド 新規のα４β７ペプチド単量体及び二量体拮抗薬
JP2018526989A (ja) 2015-08-07 2018-09-20 ピエリス ファーマシューティカルズ ゲーエムベーハー Ｌａｇ−３およびｐｄ−１に特異的な新規融合ポリペプチド
CN105504018A (zh) 2016-01-13 2016-04-20 郑州大学 Lag-3亲和肽n13、制备方法及其应用
WO2018218137A1 (en) 2017-05-25 2018-11-29 Leidos, Inc. Pd-1 and ctla-4 dual inhibitor peptides
WO2019158942A1 (en) 2018-02-16 2019-08-22 Crescendo Biologics Limited Therapeutic molecules that bind to lag3 and pd1

Also Published As

Publication number Publication date
WO2021247789A1 (en) 2021-12-09
CA3185657A1 (en) 2021-12-09
EP4161952A1 (en) 2023-04-12
US11338040B2 (en) 2022-05-24
JP2023529839A (ja) 2023-07-12
US20210379189A1 (en) 2021-12-09
AU2021283353A1 (en) 2023-02-02

Similar Documents

Publication Publication Date Title
US12370258B2 (en) PD-1 and CTLA-4 dual inhibitor peptides
US12269880B2 (en) LAG3 binding peptides
JP7733020B2 (ja) 免疫調節性化合物
US20230414703A1 (en) PD-1 Peptide Inhibitors
US11578102B2 (en) LAG3 binding peptides
AU2018410849B2 (en) PD-1 peptide inhibitors
US11987646B2 (en) Immunomodulatory peptides

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240531

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240531

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250424

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250425

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250717

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250804

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250821

R150 Certificate of patent or registration of utility model

Ref document number: 7733020

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150